Quick summary
For many people, deciding to start a weight loss medication like Mounjaro or Wegovy can feel like a deeply personal and sometimes intimidating step. Beyond the science, there’s a social side to this journey that isn’t talked about enough: the stigma.
You may have heard comments like, “Why can’t you just eat less and exercise more?” or “That’s the easy way out.” But here’s the truth — taking weight loss medication is not a sign of giving up. It’s a sign that you care about your health, that you’ve done the hard work of trying other approaches, and that you’re ready to use every tool available to become the healthiest version of yourself.
Taking Medication Doesn’t Mean You’ve Failed, It Means You’re Taking Control
Obesity and weight-related conditions are complex. They’re influenced by genetics, hormones, environment, and mental health, not just willpower. When lifestyle changes alone aren’t enough, medications like Mounjaro and Wegovy can help balance what biology makes difficult.
By starting one of these treatments, you’re not “cheating” your way to health, you’re making an informed, proactive decision to use a medically proven approach. That’s something to be proud of.
How to Talk to Friends and Family About Your Decision
Talking openly about weight loss medication can feel vulnerable, but it can also be empowering. Here are some ways to approach those conversations:
- Be confident in your choice. You might say, “I’ve discussed this with my healthcare provider and decided this is the right step for my health.”
- Keep it factual, not defensive. You don’t owe anyone an explanation, but if you want to share more, you can explain that these medications help regulate appetite and blood sugar - they’re tools, not shortcuts.
- Set boundaries. If someone is judgmental or dismissive, it’s okay to say, “This is something I’m doing for my health, and I’d appreciate your support.”
- Find your allies. Surround yourself with people who lift you up, online or offline. There’s a growing, supportive community of people on similar journeys who understand exactly what you’re going through.
Beyond the Scale: The Broader Health Benefits
While popular discussions about medications like Mounjaro and Wegovy often focus on the numbers on the scale, the evidence is increasingly clear that their benefits go well beyond weight loss. Here are some of the most important health outcomes discovered so far:
Cardiovascular health
In a large trial of ≈13,000 adults with type 2 diabetes and established cardiovascular disease, Mounjaro (tirzepatide) demonstrated an 8% lower rate of major adverse cardiovascular events (MACE-3: cardiovascular death, heart attack, or stroke) compared with dulaglutide, and a 16% reduction in all-cause mortality. [1]
For Wegovy (semaglutide), research from the SELECT trial (17,604 adults with overweight or obesity and cardiovascular disease, but no diabetes) found around a 20% reduction in heart attack, stroke or cardiovascular death. [2]
These findings suggest that the medications’ impact on heart health may come not just from weight loss, but from direct physiological effects (improved blood sugar, blood pressure, lipid profiles, etc.). [3]
Improved cardiometabolic markers
- In the Wegovy studies, beyond weight loss, participants experienced reductions in waist circumference, systolic and diastolic blood pressure, total cholesterol, LDL (bad) cholesterol, triglycerides, and gains in HDL (good) cholesterol. For example, one study found a 5.7 mmHg reduction in systolic blood pressure and a 19% reduction in triglycerides at 104 weeks with Wegovy. [4]
Kidney protection and mortality
- In the Mounjaro cardiovascular outcomes trial, a prespecified analysis suggested protection of kidney function (slowed eGFR decline) in participants at high risk of chronic kidney disease. [1]
- The data also hinted at reductions in overall mortality in certain populations. [1]
Potential mental-health/quality-of-life benefits
- Some early observational data suggest that the use of semaglutide (Wegovy) may be associated with lower risk of suicidal thoughts compared with older medications for obesity/diabetes — though this research is still emerging and should be interpreted cautiously. It’s worth emphasising: these drugs are not primarily mental-health treatments, but improved physical health, increased mobility, and fewer health worries often translate into better mood, greater confidence, and improved overall quality of life.
How to Include These in Your Conversation
When you’re talking with friends or family about your decision to use medication, you might add something like:
“What attracted me to this treatment was that it’s not just about losing weight — it’s also about lowering my heart risk, improving my blood pressure and possibly protecting my kidneys. My doctor and I reviewed the data together.”
Or, if you’re setting boundaries:
“I’m doing this because my health-check showed elevated blood pressure and cholesterol, and my doctor said this medication could help those, not just help me lose weight.”
You Deserve to Feel Proud
There’s incredible courage in deciding to take control of your health. Whether you’re just starting your journey or already seeing changes, remember that you’re not alone. And there’s nothing shameful about using medical support to achieve your goals.
You don’t just owe yourself a new number on the scale — you owe yourself better heart health, stronger metabolic health, more energy, and a life with fewer limits. Choosing a medically supported path with Mounjaro or Wegovy isn’t about vanity or weakness; it’s about health, self-respect, and the willingness to keep trying.
When you take this step, you’re giving yourself every opportunity to live your healthiest, most confident life — not just to wear smaller clothes, but to feel stronger, more vibrant, and more in control.
And when you share your story, you help shift the conversation: from “just weight” to whole-body health, from “diet shame” to empowered medicine and lifestyle, from “I’m hiding this” to “Here’s why I’m proud.”
You’ve made a powerful, informed decision — and that’s something to truly celebrate.
Wegovy is here! Start your free assessment
Mounjaro is here! Start your free assessment
References
- Eli Lilly and Company (2025). SURPASS-CVOT Topline Results: Cardiovascular and Mortality Outcomes for Tirzepatide vs Dulaglutide. [Press release]. (HR 0.92 for MACE-3; HR 0.84 for all-cause mortality). Lilly+2PR Newswire+2
- Saha A, Bavry A (2024). Semaglutide Effects on Cardiovascular Outcomes – SELECT Trial. American College of Cardiology. (17,604 participants; 20% reduction in CV death, MI or stroke over ~40 months). American College of Cardiology+2American Heart Association+2
- Schnell O, et al. (2024). Prespecified analysis of the SELECT trial: cardiovascular outcomes by baseline and changes in adiposity measures. Journal name. They found the cardioprotective effects of semaglutide were only partially mediated by reduction in waist circumference, suggesting other mechanisms beyond weight loss. PubMed
- U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research, Clinical Review of Semaglutide (Wegovy) NDA. Lipid changes over 104 weeks: −4.63% total cholesterol, −5.25% LDL-C, +4.68% HDL-C, −18.34% triglycerides.